ImmunoGen’s Global Multi-Target License Agreement with Eli Lilly

Ropes & Gray advised ImmunoGen on the deal.ImmunoGen, a leader in the field of antibody-drug conjugates for the treatment of cancer, announced a global, multi-year licensing…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Laura Testa

Author: Laura Testa

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here